Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.
Precision BioSciences, a US-based gene editing technology developer backed by pharmaceutical firms Amgen and Baxter, is in the process of raising $110m in a series B round, according to a regulatory filing.
The company has raised approximately $88m so far, though it does not appear to have made an official announcement about the round yet.
Spun out of Duke University in 2006, Precision BioSciences has developed a genome editing platform, Arcus, that relies on an enzyme called a homing endonuclease.…
